Consistently, the variant segregates with a prostate cancer case, sustaining the observation that BRCA2 variants are predominantly associated with increased risks of breast and prostate cancers (Lecarpentier et al., 2017) and less with colon cancer. This evidence concerns the gene BRCA2 and prostate carcinoma.